Medical News

RSS

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.

12 Mar 2010

Stimulus funds boost Utah health IT pipeline

Utah's health department will use $6.3 million in federal dollars to build a "computer pipeline" that will allow doctors and hospitals to share patient information, The Salt Lake Tribune reports.

12 Mar 2010

Hooper Holmes' revenues for fourth-quarter of 2009 decline by 5%

Hooper Holmes today announced financial results for the fourth quarter and year ended December 31, 2009.

12 Mar 2010

Maternal health care crisis in the U.S.: 15.8% of women in Georgia receive delayed or no prenatal care

In releasing a new report on maternal health nationwide, Amnesty International today revealed that flaws and shocking disparities in maternal health care that the government is ignoring lead to two to three women dying daily in the United States from pregnancy-related complications, with half of these deaths believed preventable, according to the Centers for Disease Control. A state-by-state examination shows that Georgia is 50th on a maternal mortality ranking, with 20.5 deaths per 100,000 live births.

12 Mar 2010

Experts: Americans get too many tests, too much treatment

"Too much cancer screening, too many heart tests, too many cesarean sections. A spate of recent reports suggest that too many Americans -- maybe even President Barack Obama -- are being overtreated." Defensive medicine and a culture focusing on medical technology have lead to overtesting but "now new evidence and guidelines are recommending a step back and more thorough doctor-patient conversations about risks and benefits."

12 Mar 2010

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

BeaconEquity.com announces an investment report featuring biotechnology company BioSante Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

12 Mar 2010

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Ardea Biosciences, Inc. (Nasdaq: RDEA) a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments, announced fourth quarter and full-year 2009 financial results and provided key upcoming clinical development milestones and financial guidance for 2010.

12 Mar 2010

FDA accepts proposed proprietary name Exelbine for ADVENTRX Pharmaceuticals' ANX-530

ADVENTRX Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the proposed proprietary name "Exelbine™" for the Company's product candidate ANX-530 (vinorelbine injectable emulsion).

12 Mar 2010

Life insurance industry is for faster pace of change in the use of technology

The long-term outlook for the life insurance industry is for a faster pace of change, particularly in the use of technology. That was the conclusion of a survey of top industry executives by LOMA.

12 Mar 2010

Childhood obesity: Genetic variation could be a factor

Increasing childhood obesity has worried governments and public health advisers in many countries. But a study of 300 children with severe obesity by the University of Cambridge and the Wellcome Trust Sanger Institute, suggest the problem may be more complicated than simply bad diet, overeating, or lack of exercise.

12 Mar 2010

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability.

12 Mar 2010

Antibiotics lower risk of developing gastric cancer

Helicobacter pylori, a bacterium found in about 50% of humans worldwide, can cause stomach ulcers and, in extreme cases, gastric cancer. In an article for F1000 Medicine Reports, Seiji Shiota and Yoshio Yamaoka discuss the possible eradication of H. pylori infections

12 Mar 2010

St. Jude Medical to exhibit cardiac clinical solution products portfolio at ACC 2010

St. Jude Medical, Inc. today announced it will display products and technologies from the company’s wide array of clinical solutions in the cardiology, cardiac surgery, atrial fibrillation and cardiac rhythm management markets at ACC 2010.

12 Mar 2010

$Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur$

Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur

Bisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons.

12 Mar 2010

Genetix Pharmaceuticals announces completion of $35M Series B financing

Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team.

12 Mar 2010

Pregnancy-related deaths increase in Michigan, Amnesty International report

In releasing a new report on maternal health nationwide, Amnesty International today revealed that flaws and shocking disparities in maternal health care that the government is ignoring lead to two to three women dying daily in the United States from pregnancy-related complications, with half of these deaths believed preventable, according to the Centers for Disease Control. A state-by-state examination shows that Michigan is 42nd on a maternal mortality ranking, with 13.6 deaths per 100,000 live births.

12 Mar 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for full year and fourth quarter, ended December 31, 2009. These results are included in the Company’s Annual Report on Form 10-K which has been filed with the SEC.

12 Mar 2010

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

GTC Biotherapeutics, Inc. today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.

12 Mar 2010

Verisk Health upgrades Explorer product line to improve organization’s exposure to healthcare risk

Verisk Health, Inc., a global leader in healthcare data analytics and risk management, today announced several upgrades to its Explorer product line, including functionality that allows users to evaluate the impact of a member’s lifestyle behaviors on an organization’s overall healthcare and utilization costs.

12 Mar 2010

Manhattan Pharmaceuticals to merge with Ariston Pharmaceuticals

Manhattan Pharmaceuticals, Inc. today announced it has entered into a definitive agreement and plan of merger and completed the merger transaction with Ariston Pharmaceuticals, Inc., a privately-held, specialty pharmaceutical company. As a result of the merger, Ariston became a wholly owned subsidiary of Manhattan Pharmaceuticals.

12 Mar 2010

Medical News

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

Stimulus funds boost Utah health IT pipeline

Hooper Holmes' revenues for fourth-quarter of 2009 decline by 5%

Maternal health care crisis in the U.S.: 15.8% of women in Georgia receive delayed or no prenatal care

Experts: Americans get too many tests, too much treatment

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

FDA accepts proposed proprietary name Exelbine for ADVENTRX Pharmaceuticals' ANX-530

Life insurance industry is for faster pace of change in the use of technology

Childhood obesity: Genetic variation could be a factor

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

Antibiotics lower risk of developing gastric cancer

St. Jude Medical to exhibit cardiac clinical solution products portfolio at ACC 2010

Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur

Genetix Pharmaceuticals announces completion of $35M Series B financing

Pregnancy-related deaths increase in Michigan, Amnesty International report

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

Verisk Health upgrades Explorer product line to improve organization’s exposure to healthcare risk

Manhattan Pharmaceuticals to merge with Ariston Pharmaceuticals

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Latest News